Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 12;2012(1):22.
doi: 10.1186/1687-9856-2012-22.

Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies

Peter A Lee  1 , Lars Sävendahl, Isabelle Oliver, Maithé Tauber, Oliver Blankenstein, Judith Ross, Marta Snajderova, Viatcheslav Rakov, Birgitte Tønnes Pedersen, Henrik Thybo Christesen
Affiliations

Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies

Peter A Lee et al. Int J Pediatr Endocrinol. .

Abstract

Background: Few studies have compared the response to growth hormone (GH) treatment between indications such as isolated growth hormone deficiency (IGHD), born small for gestational age (SGA), idiopathic short stature (ISS), and multiple pituitary hormone deficiency (MPHD). The aim of this analysis of data, collected from two large ongoing observational outcome studies, was to evaluate growth and insulin-like growth factor-I (IGF-I) response data for children of short stature with IGHD, MPHD, SGA, or ISS following two years of treatment with the recombinant GH product Norditropin® (Novo Nordisk A/S, Bagsværd, Denmark).

Methods: Analysis of auxologic data from two ongoing prospective observational studies, NordiNet® International Outcomes Study (NordiNet® IOS) and NovoNet®/American Norditropin®

Studies: Web-enabled Research (ANSWER) Program®.

Results: 4,582 children aged <18 years were included: IGHD, n = 3,298; SGA, n = 678; ISS, n = 334; and MPHD, n = 272. After two years' GH treatment, change in height standard deviation score (SDS) was +1.03 in SGA and +0.84 in ISS vs. +0.97 in IGHD (p = 0.047; p < 0.001 vs. IGHD, respectively). Height gain was comparable between IGHD and MPHD. In pre-pubertal children vs. total population, height SDS change after two years was: IGHD, +1.24 vs. +0.97; SGA, +1.17 vs. +1.03; ISS, +1.04 vs. +0.84; and MPHD, +1.16 vs. +0.99 (all p < 0.001).

Conclusions: After two years' GH treatment, change in height SDS was greater in SGA and less in ISS, compared with IGHD; the discrepancy in responses may be due to the disease nature or confounders (i.e. age). Height SDS increase was greatest in pre-pubertal children, supporting early treatment initiation to optimize growth outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean height SDS at baseline, one year and two years and change in height SDS at one year and two years by indication.
Figure 2
Figure 2
Mean IGF-I SDS at baseline, one year and two years by indication.
See this image and copyright information in PMC

References

    1. Gharib H, Cook DM, Saenger PH. et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children – 2003 update. Endocr Pract. 2003;9(1):64–76. - PubMed
    1. Cohen P, Rogol AD, Deal CL. et al.Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93(11):4210–4217. doi: 10.1210/jc.2008-0509. - DOI - PubMed
    1. Carel JC, Ecosse E, Nicolino M. et al.Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. Br Med J. 2002;325(7355):70. doi: 10.1136/bmj.325.7355.70. - DOI - PMC - PubMed
    1. Takeda A, Cooper K, Bird A. et al.Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14(42):1–209. iii–iv. - PubMed
    1. Maghnie M, Ambrosini L, Cappa M. et al.Adult height in patients with permanent growth hormone deficiency with and without multiple pituitary hormone deficiencies. J Clin Endocrinol Metab. 2006;91(8):2900–2905. doi: 10.1210/jc.2006-0050. - DOI - PubMed